Reuters -- Britain’s GlaxoSmithKline and Denmark’s Genmab said on Tuesday that U.S. officials have delayed the deadline by which they expect to rule on their leukaemia treatment Arzerra by three months.
Reuters -- Britain’s GlaxoSmithKline and Denmark’s Genmab said on Tuesday that U.S. officials have delayed the deadline by which they expect to rule on their leukaemia treatment Arzerra by three months.
